Fax: (212) 989-0846
Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations
A qualitative study of patient preferences
Article first published online: 26 JUN 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 24, pages 6270–6277, 15 December 2012
How to Cite
Hurley, K., Rubin, L. R., Werner-Lin, A., Sagi, M., Kemel, Y., Stern, R., Phillips, A., Cholst, I., Kauff, N. and Offit, K. (2012), Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations. Cancer, 118: 6270–6277. doi: 10.1002/cncr.27695
- Issue published online: 3 DEC 2012
- Article first published online: 26 JUN 2012
- Manuscript Accepted: 14 MAY 2012
- Manuscript Revised: 11 MAY 2012
- Manuscript Received: 26 JAN 2012
- preimplantation diagnosis;
- neoplastic syndromes;
- genetic counseling;
- health communication;
- BRCA1 gene;
- BRCA2 gene
Studies have shown that BRCA1/2 mutation carriers are interested in learning about reproductive options such as preimplantation genetic diagnosis (PGD) to prevent passing their risk onto their children. However, attitudes vary widely, and the procedure raises complex ethical and psychosocial issues. This complexity, plus the highly technical nature of PGD, makes it difficult to integrate PGD information into genetic counseling sessions that already cover probabilistic, emotionally charged risk information.
A total of 33 carriers of the BRCA1/2 mutation who were of reproductive age and had previously undergone genetic counseling viewed a tutorial regarding PGD and were interviewed concerning their attitudes toward PGD and preferences about how to include PGD information in genetic counseling.
The majority of participants preferred to be briefly informed of the availability of PGD information, and to receive written materials regarding PGD, but with the option of deferring detailed discussion if they already believed themselves to be overloaded or perceived that PGD was not immediately relevant to their risk management and/or childbearing plans. For some individuals, the stress of testing temporarily interfered with information processing, producing states of cognitive avoidance (“in a fog,” or “tuning out”). Some preferred to discuss PGD with a physician with whom they had an ongoing relationship (eg, obstetrician/gynecologist, primary care provider, or oncologist).
Providers offering cancer genetic testing may consider indicating the availability of PGD information to their patients, while attending to the patients' level of interest and ability to absorb information. Research is needed to link patient responses to information overload with psychosocial outcomes (eg, distress, and quality of decision-making). Continuing medical education is needed to support providers in facilitating informed decisions regarding PGD. Cancer 2012. © 2012 American Cancer Society.